Interaction studies of risk proteins in human induced neurons reveal convergent biology and novel mechanisms underlying autism spectrum disorders

Sequencing studies of autism spectrum disorders (ASDs) have identified numerous risk genes with enriched expression in the human brain, but it is still unclear how these genes converge into cell type-specific networks and how their encoded proteins mechanistically contribute to ASDs. To address this question, we performed brain cell type-specific interaction proteomics to build a protein-protein interaction network for 13 ASD risk genes in human excitatory neurons derived from iPS cells. The network contains many (>90%) reproducible interactions not reported in the literature and is enriched for transcriptionally perturbed genes observed in layer 2/3 cortical neurons of ASD patients, indicating that it can be explored for ASD-relevant biological discovery. We leveraged the network dataset to show that the brain-specific isoform of ANK2 is important for its interactions with synaptic proteins and characterized a PTEN-AKAP8L interaction that influences neuronal growth through the mTOR pathway. The IGF2BP1-3 complex emerges as a point of convergence in the network, and we showed that this complex is involved in a transcriptional circuit concentrating both common and rare variant risk of ASDs. Finally, we found the network itself enriched for ASD rare variant risk, indicating that it can complement genetic datasets for prioritizing additional risk genes. Our findings establish brain cell type-specific interactomes as an organizing framework to facilitate interpretation of genetic and transcriptomic data in ASDs and illustrate how both individual and convergent interactions lead to biological insights into the disease.


Introduction
Autism spectrum disorders (ASDs) comprise a group of heritable neurodevelopmental conditions associated with challenges in social interaction, cognition, and behavior. In recent . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021. 10.07.21264575 doi: medRxiv preprint 3 years, substantial progress has been made in understanding the genetic architecture of ASDs, establishing that their clinical manifestations reflect polygenic contributions from both common and rare genetic risk variants across a wide spectrum of allele frequencies (1-9). While common variants account for most of ASD heritability (3), rare variants have larger effect sizes, affect protein-coding genes (10), and are therefore more easily amenable to reductionistic experimental analyses and functional interpretation (11). However, even though some ASD risk genes implicated by rare variants immediately incriminate specific physiological processes and molecular mechanisms, such as chromatin remodeling and synaptic morphogenesis (12,13), the majority do not individually offer a comprehensive picture of the biology of autism. More broadly, it remains to be determined to which extent ASD risk genes integrate into high-order pathways and networks (hereafter, we will collectively refer to these as networks) during neurodevelopment (14,15) and which insights grouping genes in such cell type specific networks will offer.
Integration of genetic and protein-protein interaction (PPI) data has shown that genes implicated in immunological, metabolic, and cardiovascular diseases often converge into PPI networks (16)(17)(18)(19). In the context of ASDs, early studies of de novo mutations and structural variation in risk genes also suggested that their encoded proteins form PPI networks (20-22). These studies establish that PPIs can provide a systematic framework for biological interpretation of ASD risk genes, however, they overwhelmingly relied on PPI data derived from public databases and thus lack cell type specificity, as experiments from highly proliferative and immortalized cell types (e.g., HEK or cancer cell lines) are vastly over-represented in these databases (18,23,24).
Recent developments in genetics, transcriptomics, and induced pluripotent stem cell (iPSC) technology have now opened up the possibility to address this limitation. Indeed, integration of genetic and transcriptomic datasets has shown that genes expressed in excitatory neurons are . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021. 10.07.21264575 doi: medRxiv preprint 4 particularly enriched for genetic risk in ASDs (10,25). Furthermore, analyses of brain gene coexpression and regulatory networks (26), as well as single-cell RNA sequencing in postmortem brain tissues from patients and controls (27)(28)(29)(30), have also identified cortical excitatory neurons as a key cell type in ASDs. In tandem, new iPSC protocols for producing large numbers of induced neurons (iNs) that resemble cortical excitatory neurons, provide the opportunity to systematically execute interaction proteomics in an in vitro neuronal cell model of key relevance to ASDs (31,32).
In this study, we brought together emerging catalogs of risk genes, a cell model of human cortical excitatory neurons, proteomic approaches, and computational modeling to build a brain cell type-specific PPI network for ASD risk proteins. Specifically, through data integration of 26 immunoprecipitation (IP) experiments of 13 ASD risk proteins performed in iNs, we generated a combined brain cell type-specific PPI network in which >90% of the protein interactions are unreported in the literature, likely due to their selective expression in the brain. These data are nevertheless highly reproducible (>91% validation rate) and strongly overlap with interactions of the same proteins identified from IPs performed in human brain homogenates, indicating that iNs can capture PPIs present in analogous complex human primary tissues. As further support for the iN cell model, we found the network significantly enriched for transcriptionally perturbed genes in layer 2/3 cortical neurons of non-genetically profiled ASD patients, which agrees with previous evidence that specifically implicates this key cell type in ASD pathophysiology. To exemplify how perturbing specific PPIs in the network can lead to mechanistic insights and ASD-relevant cellular phenotypes, we showed that ablating a giant brain-specific ANK2 alternative exon, which concentrates mutations observed in ASD patients, resulted in loss of isoform-specific interactions with synaptic proteins, while disrupting a newly found PTEN-AKAP8L interaction affected . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021. 10.07.21264575 doi: medRxiv preprint neuronal growth. Furthermore, convergent signals in the network can also provide important insights, as illustrated by the mRNA-binding complex IGF2BP1-3, which is connected to multiple ASD risk proteins in the network and is at the center of a transcriptional circuit enriched for both common and rare variant risks of ASDs. Finally, the network is also enriched for genes containing rare ASD-associated variants, indicating that it can complement large-scale genetic studies to prioritize additional risk genes.
In summary, our study demonstrates how brain cell type-specific interaction proteomics represents a rich and currently underutilized opportunity for biological discovery in ASDs, providing a rich community resource to catalyze interpretation of genetic and scRNA datasets. Our results lay a foundation for future discovery of biomarkers or targets for therapeutic intervention.
As a substrate for cell type-specific analyses of the index genes and proteins, we adopted and further optimized NGN2 programming combined with developmental patterning as previously . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint 6 described by Nehme et al. (31) to differentiate iPSCs into iNs. In particular, we used an iPS cell line (iPS3, Methods) where the neurogenic factor Neurogenin 2 (NGN2) is integrated in the genome under a tetON promoter for rapid and controlled doxycycline-induced expression, resulting in highly homogeneous iN populations ( Figure 1B).
We measured the expression of ASD index genes through RNA sequencing of cells during weeks 0, 3, and 6 of neuronal differentiation ( Figure 1C). The expression patterns of these genes varied across time, with some genes showing decreased (e.g., MED13L) or increased (e.g., CHD8) expression levels at later time points. Generally, most index genes were expressed after three weeks of differentiation, including genes (i.e., GRIN2B, SCN2A, and SHANK3) with previously reported neuronal identity (33). Importantly, gene expression observed in iNs as early as week 3 ( Figure 1C) resembled expression patterns seen in excitatory neuron populations of the human cortex (Supplementary Figure 1A,B) (30), supporting this cell model as a proxy for cell types in the human brain.
Next, we sought to identify immunoreagents to detect and immunoprecipitate index proteins in iNs. After testing ~60 antibodies (Supplementary Table 1), we concluded that there were no adequate commercial reagents for detection of seven proteins (ASH1L, CHD2, DSCAM, FOXP1, KDM6B, KMT5B, SLC6A1), based on western blots executed on a range of cells and tissues (i.e., mouse cortex and HEK293 cells; Figure 1D) included as positive controls.
Furthermore, four proteins (ANKRD11, DEAF1, GRIN2B, POGZ) were successfully detected by immunoblotting (Supplementary Figure 1C), but no immunoreagent was IP-competent. The remaining 13 proteins could be detected by immunoblotting in the form of at least one protein isoform at week 3 of iN differentiation ( Figure 1E) and were amenable to IP.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. The protein expression analysis revealed that many index proteins show distinct isoform patterns across species (e.g., TLK2 in mouse cortex), neuronal differentiation time points (e.g., SHANK3 in iPSCs), or cell types (e.g., CHD8 in HEK293 cells; Figure 1E). This observation highlights the importance of using human iNs in order to capture cell type-specific biochemical interactions of relevance to ASDs.

Figure 1. Study workflow and expression of ASD index genes and proteins in human iNs. (a)
Schematic of the experimental and computational workflow to generate an ASD PPI network in . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   Table 2). Each experiment was conducted in duplicates using ~15 million cells per replicate, and protein abundances in the IP samples were quantified using labeled or label-free liquid chromatography followed by tandem mass spectrometry (LC-MS/MS). In total, we conducted 37 IP-MS experiments for the 13 index proteins, generating 2-5 experimental datasets for each protein.

Interaction proteomics of index proteins in induced neurons
For each IP-MS experiment, we performed quality control (QC) and data analysis using Genoppi (24). Specifically, we calculated the log2 fold change (FC) and corresponding statistical significance of each protein identified in the index protein IPs compared to control IPs . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  Table 2). After filtering out 11 datasets that did not pass QC thresholds (i.e., log2 FC correlation between replicates was ≤ 0.6 or the index protein was not positively enriched at FDR ≤ 0.1), 26 high-quality datasets were used for all downstream analyses. In each dataset, we defined proteins with log2 FC > 0 and FDR ≤ 0.1 as 'significant interactors' of the index protein; the rest of the detected proteins were defined as 'non-interactors' (Supplementary Table 3). We also systematically intersected each dataset with known protein interactors of the index protein from the InWeb_InBioMap (InWeb) database (23, 34), which aggregates human PPI data from > 40k published articles (Supplementary Table 3). This allowed us to assess if the identified interactions have been reported in the literature or are potentially novel.
We exemplify our analysis workflow using an IP of SHANK3: enrichment of SHANK3 in the IP was confirmed by immunoblotting (Figure 2A, left), and quantified in the IP-MS data (log2 FC = 1.2 and FDR = 0.012; Figure 2B). The IP-MS replicate log2 FC correlation is 0.79 (Figure   2A, right). Only two out of 104 significant interactors were previously reported in InWeb, suggesting that 98% of the interactions reported here are new ( Figure 2B). Overall, the clear enrichment of SHANK3 both in the immunoblot of the IP and in the MS results, in combination with the high correlation between replicates, support the reproducibility and robustness of our data.
The low number of known SHANK3 interactors supports the use of neuron-specific proteomics to discover new ASD risk gene relationships.

The ASD PPI network consists of many convergent, novel, and reproducible interactions
After analyzing each IP-MS dataset individually, we merged all the interactors identified across the 26 high-quality datasets to generate a combined PPI network for all 13 index proteins.
This network comprises 1,021 proteins interacting with at least one index protein ( Figure 2C and . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  Table 3). The PPI network shows high interconnectivity, with > 20% of interactors being shared by more than one index protein ( Figure 2D and Supplementary Figure   3A). Furthermore, whereas the interactors of several index proteins (ANK2, ARID1B, CTNNB1, DYRK1A, MED13L) are enriched for known InWeb interactors (Supplementary Table 3 To compare our data to protein interactions in the human brain, we also performed IP-MS experiments for a subset of index proteins (ANK2, DYRK1A, SCN2A, SHANK3, SYNGAP1) in postmortem brain homogenates (Supplementary Table 2). On average, brain IP-MS datasets have lower log2 FC correlations between replicates compared to the iN IP-MS data (average correlation = 0.63 and 0.72 for brain and iN IPs, respectively; Supplementary Table 2). This is likely reflecting noise and experimental artefacts of interaction proteomics executed in complex samples that comprise a mix of cell types and are not renewable. After applying the same QC metrics as previously described, we considered three of the brain IPs (for SCN2A, SHANK3, and . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint SYNGAP1) to be high-quality and compared the interactors identified in these IPs with the analogous iN-derived interactors ( Figure 2F and Supplementary Figure 3E,F). Considering that the brain homogenates contain a mix of cells whereas the iNs are highly homogeneous, we observed a remarkable and statistically significant overlap between the interactors identified in the two sample types, with 42% of the brain interactors also identified as interactors in iNs (P = 2.6e-13). Throughout brain development (35) (www.brainspan.org), both brain-and iN-derived interactors have elevated gene expression in the cortex compared to random genes; in particular, interactors that were identified in both sample types have an expression profile that is comparable to ASD risk genes identified through exome sequencing (Supplementary Figure 4A,B). These results strongly support that our findings in iNs recapitulate those from a complex biological tissue in the human brain.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. showing the overlap between interactors for SCN2A, SHANK3, and SYNGAP1 derived from IP-MS experiments performed in iNs vs. human brain homogenates. Overlap enrichment P-value was calculated using a one-tailed hypergeometric test that only considered the population of proteins detected in both iN and brain IPs.

The PPI network is transcriptionally perturbed in layer 2/3 cortical excitatory neurons of patients with ASDs
We assessed the tissue specificity of the network by calculating its overlap enrichment with GTEx tissue-specific genes (36) compared to the rest of the genome. As expected, the network showed statistically significant enrichment (P < 0.05/53, adjusting for 53 tissues) in the central nervous system, as well as in several other tissue categories ( Figure 3A and Supplementary Table 5). When the analysis was repeated using brain region-specific genes, the network showed significant enrichment (P < 0.05/13, adjusting for 13 brain regions) in the frontal cortex, cerebellar hemisphere, anterior cingulate cortex, and amygdala ( Figure 3B and Supplementary Table 5).
In addition, we performed SynGO (37) gene set analysis to confirm that the PPI network is enriched for genes involved in biological processes in the synapse, such as "protein translation at . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  Table   5).
To link the network to specific cell types that are implicated in ASDs, we integrated our data with a recent single-cell RNA sequencing study (30), which measured gene expression in the postmortem cortex of ASD patients versus healthy controls and identified differentially expressed genes (DEGs) between the two groups in 17 annotated cell types. First, we performed a 'global' enrichment analysis to test whether the network genes show enriched overlap with commonly expressed genes in a cell type (i.e., expressed in >50% of cells in the cell type) compared to other genes in the genome. We also performed a more restricted 'conditional' enrichment analysis that compared the overlap of network genes to that of other genes whose proteins were also expressed in iNs (i.e., non-interactors detected in our IP-MS experiments, which did not show significant interaction with any of the index proteins; Supplementary Table 3 Table 5).
Next, we tested the global and conditional enrichment of the network in terms of its overlap with cell type-specific DEGs in ASD patients compared to controls. In the global analysis, our network showed significant enrichment in several cell types including excitatory neurons, inhibitory interneurons, astrocytes, and microglia (Supplementary Figure 4E and Supplementary Table   5). Strikingly, in the more conservative conditional analysis, the layer 2/3 excitatory neurons stand out as the only significant cell type (P < 0.05/17; Figure 3D and Supplementary Table 5).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint Taken together, these results firmly establish that the PPI network captures biochemical perturbations and pathways in ASD-relevant tissues and cell types, and specifically implicate layer 2/3 excitatory neurons as a key cell type for ASD pathophysiology.  log 10 (P −value) Brain tissue b . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Dissecting isoform-specific PPIs in the network: giant ANK2 knockout leads to loss of

neuron-specific interactions in maturing neurons
A number of index genes in this study are disrupted in ASDs in an isoform-specific manner. This is the case for giant ankyrin-2 (ANK2) (38), a non-canonical and neurospecific alternatively spliced variant of the ANK2 gene (39). This isoform is differentiated from canonical ANK2 due to inclusion of exon 37 (giant exon) encoding 9,240 amino acids, which contains the majority of the mutations identified in ASD patients ( Figure 4A). When modeled in mice, human ASD-associated mutations of ANK2 led to gain of axon branching in the central nervous system, a phenotype that is hypothesized to originate from loss of giant ANK2-specific interactions (38). While we validated numerous ANK2 interactors identified from the IP-MS experiments performed in iNs . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint ( Figure 4B, Supplementary Figure 5A, and Supplementary Table 4), they are likely a mix of interactors of all ANK2 isoforms. Thus, to focus specifically on the ASD-relevant ANK2 isoform we increased the resolution of our interaction data by building an in vitro model of selective loss of giant ANK2 using CRISPR/Cas9 gene editing (Figure 4C).
We edited an iPS cell line (iPS3, Methods) to exclude retention of exon 37, which differentiates the giant ANK2 from canonical (short) ANK2 isoforms (Figure 4D, top). Fully characterized giant ANK2 knockout (KO) iPSCs (Figure 4D, bottom) were viable, but showed visible morphological defects upon neuronal differentiation, defective ANK2 distribution, and resulted in high cell death (data not shown). We could not collect sufficient giant ANK2 KO iNs for IP-MS due to high cell death during neuronal maturation. Nonetheless we performed immunoblot analysis in KO iNs to test for presence of selected ANK2 interactors identified by IP-MS in corresponding wild-type (WT) neurons. KO iNs were still expressing proteins essential for various aspects of neuronal physiology, including the calcium channel subunit CACNA2D and the complement protein C3, but these proteins were no longer associated with ANK2 (Figure 4E), suggesting that their localization might rely on ANK2-dependent cytoskeletal architecture.
We also performed IP-MS experiments of ANK2 in WT and giant ANK2 KO isogenic neural progenitor cells (NPCs) after one week of neuronal induction, and identified a number of ANK2 interactors that are specific to either WT (which express both canonical and giant ANK2 Table 2 and Supplementary Figure 5B). GO analysis of differential interactors shows that the most enriched cellular component for the WT-specific interactors is "glutamatergic synapses", while the KO-specific interactors is most enriched for "microtubules" (Supplementary Table 6). These results suggest the giant ANK2 isoform plays a central role in localizing the protein to form cell projections of maturating NPCs and in guiding . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint neuronal morphology. This hypothesis is further supported by the observation that ARPC5L is amongst the ANK2-WT-specific interactors. ARPC5L is a component of the ARP2/3 complex that regulates the synthesis of branched actin networks and is essential for both structural and functional maturation of the growth cone in maturating neurons (40).
These observations collectively suggest that the wide range of functional defects previously observed in giant ANK2 loss-of-function (LoF) models first result from mis-localization of giant ANK2-specific interactors. Severe defects in cell morphogenesis could be a secondary effect. This vignette demonstrates the potential of using cell type-specific and isoform-specific PPI networks to gain detailed mechanistic insights into ASDs.

Perturbing a newly found PPI in the network: AKAP8L knockout phenocopies PTEN's cellular phenotype in iNs
We next performed functional follow-up experiments to investigate a newly identified interaction found in the PTEN IPs. PTEN encodes a phosphatase that acts as a tumor suppressor by antagonizing PI3K/AKT/mTOR signaling (41). PTEN is mutated at high frequency in a large number of cancers, but germline mutations of PTEN have also been described in a subset of patients with autism and macrocephaly (42). However, it is unclear whether cell proliferation caused by disruption of mTOR signaling upon PTEN mutation can also be linked to these . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint developmental disorders (43). To address this question, we further explored the PTEN interactors found by IP-MS in iNs.
Surprisingly, the most robust interactor we identified for PTEN in iNs is the A-kinase anchor protein AKAP8L (Figure 5A), which has not been associated with PTEN in previous biochemical studies (that were almost exclusively conducted in cancer cell models or tissues), suggesting a neuron-specific mTOR circuitry of PTEN that acts through AKAP8L. The PTEN-AKAP8L interaction was replicated using two independent PTEN antibodies for IP-MS (data not shown) and consistently validated by immunoblotting and reverse IP ( Figure 5B, Supplementary   Figure 5C).
We generated AKAP8L KO (-/-) iPS cell lines through CRISPR/Cas9 gene editing ( Figure   5C) to test if they phenocopy neurodevelopmental phenotypes observed in individuals with PTENassociated autism and macrocephaly. We obtained isogenic lines with both heterozygous (+/-) and homozygous (-/-) AKAP8L mutations, with the homozygous KO line resulting in complete loss of AKAP8L ( Figure 5D). Interestingly, the AKAP8L homozygous KO line showed a statistically significant increase in growth rate at the NPC stage, compared to isogenic wild-type and heterozygous lines (P = 0.0287 and 0.0162, respectively; Figure 5E).
To gain deeper mechanistic insights we tested whether this cellular phenotype is linked to a neuron-specific circuitry that includes the mTOR pathway. Although AKAP8L KO did not result in changes of PTEN levels in iNs as measured by immunoblotting, we did observe a small, but detectable increase in the levels of phosphorylated ribosomal protein S6 (Figure 5F). This is a marker of hyperactivation of the mTOR pathway and suggests an AKAP8L-mediated defect in the PTEN signaling cascade in ASDs. Taken together, our results illustrate a neuronal variation on the PTEN-mTOR circuitry that includes AKAP8L and specifically suggest that the PTEN-AKAP8L . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Network convergence implicates the IGF2BP1-3 complex in an ASD-relevant transcriptional and protein interaction circuitry
Since the combined PPI network derived from all IP-MS datasets identified a number of interactors linked to multiple index proteins (Figure 2C,D; Supplementary Table 3), we hypothesized that the degree of convergence in the network could be used to discover biological themes of relevance to ASDs. By ranking proteins in descending order based on the number of index proteins they interact with (Supplementary Table 3), we noticed that three insulin-like growth factor 2 mRNA-binding proteins, IGF2BP1, 3, and 2, are all among the top ten recurring interactors and are associated with seven, six, and five of the index proteins, respectively. All three . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Together, they form a N6-methyladenosine (m6A)-reader complex broadly involved in posttranscriptional regulation by impacting mRNA stability and translation (44). We therefore set out to test the hypothesis that this complex is implicated in ASDs through a circuit connecting transcription of ASD risk genes to the protein network that we have identified. We analyzed published RNA targets of IGF2BP1-3 identified in HEK cells (44) and found that targets of each protein individually, as well as their combined targets, are all significantly enriched for ASD risk genes identified through exome sequencing (10) (P = 3.9e-10 for the combined target list; Figure   6A, Supplementary Table 7); among these risk genes are also nine of the index genes in this study.
Genetic risk enrichment analysis using ASD GWAS data (45) and MAGMA (46) also found the IGF2BP1-3 targets to be enriched for common variant risk of ASDs (P = 1.4e-3 for the combined target list; Figure 6B, Supplementary Table 7). Furthermore, we performed a conditional enrichment analysis to test whether genes in our combined PPI network and index protein-specific sub-networks are enriched for IGF2BP1-3 targets compared to the non-interactors detected in our neuronal proteomic data (Figure 6C, Supplementary Table 7). At a Bonferronicorrected significance threshold (P < 0.05/56, adjusting for 14 networks and 4 IGF2BP target lists), the combined and DYRK1A networks both show significant enrichment for IGF2BP1-3 targets (P = 1.7e-17 and 7.6e-9 for the combined target list, respectively).
DYRK1A is a ubiquitously expressed protein kinase encoded by a gene localized in the Down syndrome critical region of chromosome 21 and is strongly associated with learning defects . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint associated with Down syndrome (47) and ASDs (48). DYRK1A has been implicated in posttranscriptional regulation of different cellular processes involved in brain development and function, ranging from early embryogenesis through late aging (49). Thus, given the enriched overlap observed between the IGF2BP1-3 targets and the DYRK1A network, we hypothesized that DYRK1A might be part of an ASD-relevant feedback circuitry acting upstream of the IGF2BP1-3 complex. To test this hypothesis, we first verified that the interactions between DYRK1A and IGF2BP1-3 identified by IP-MS ( Figure 6D) are not mediated by nucleic acids, hence indicating a direct regulatory relationship between DYRK1A and the IGF2BP1-3 complex ( Figure 6E). Next, we performed siRNA knockdown of DYRK1A in iPSCs, and observed that partial knockdown was sufficient to trigger increased expression of IGF2BP1-3 ( Figure 6F).
Overall, our results suggest that the IGF2BP1-3 complex regulates an ASD-relevant transcriptional circuitry, and that the newly found interactions between DYRK1A and the complex might be key in modulating the expression of numerous ASD-relevant genes.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint Network RNA targets 4 8 12 16 log 10 (P −value) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021.

The network is enriched for rare variant risks of ASDs and developmental disorders
To evaluate whether the combined PPI network and index protein-specific sub-networks are enriched for genetic risks of ASDs, we performed global and conditional enrichment analyses using rare variant association statistics derived from exome sequencing of ASD patients and controls (10). In the global analysis, we tested whether genes in the networks are more significantly associated with ASDs compared to other protein-coding genes in the genome. In the conditional analysis, we compared the association scores of the network genes against that of the noninteractors detected in our neuronal proteomic data. Five networks (combined, ANK2, CHD8, . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021.  (Supplementary Figure 6A), and only the combined network was significant (P = 1.1e-5) in the conditional analysis ( Figure 7A and Supplementary Table 8). Notably, the conditional enrichment was robust even after we removed known InWeb interactors from the combined network (P = 5.5e-5; Supplementary Figure 6B), supporting that this signal is not driven by the proteome of the neuronal cell model or the known interaction partners of the index proteins. Rather, the novel, neuron-specific interactions identified in this study are enriched for rare variant risk of ASDs over and above a background set of proteins expressed in iNs. We also performed analogous enrichment analyses using exome sequencing data for developmental disorders (DD) (50) and schizophrenia (SCZ) (51) and gnomAD (52) pLI scores, which represent the probability of a gene being loss-of-function intolerant (Figure 7A, Supplementary Figure   6A,B, and Supplementary Table 8). In the conditional analysis, we observed that the combined network is significantly enriched for DD genes (P = 6.2e-7) and genes with high pLI scores (P = 2.6e-31); five index protein-specific sub-networks (ANK2, ARID1B, CHD8, DYRK1A, SYNGAP1) are also enriched for high pLI scores (P = 1.1e-12 to 3.4e-4). In contrast, there was no significant SCZ enrichment for any of the networks. Overall, these results indicate that the interactors that we have identified contribute to rare variant risks of both ASDs and DD more than one would expect for genes generally expressed in neurons. The interactors are also more likely to be intolerant to loss-of-function mutations, suggesting that they might be essential for cell fate specification or survival.
Next, in order to assess the common variant risk enrichment of the PPI networks, we performed global and conditional analyses using ASD GWAS data (45) and MAGMA (46). Only the SYNGAP1 network reached nominal significance in both the global and conditional analyses . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint (conditional P = 3.71e-3, which is just shy of the Bonferroni-corrected threshold of P < 0.05/14; Table 9). We also repeated the MAGMA analyses using GWAS data of other psychiatric disorders, including attention deficit hyperactivity disorder (ADHD) (53), bipolar disorder (BIP) (54), major depressive disorder (MDD) (55), and SCZ (56), as well as height (57) as an additional control trait. While several networks were nominally significant for some of these phenotypes, none reached Bonferroni significance (Supplementary Figure 6C and Supplementary Table 9). Given that the GWAS for ASDs and other psychiatric disorders had relatively modest sample sizes (~46k to 77k samples, except for MDD which had 500k samples), repeating these analyses when better-powered GWAS become available in the future may allow us to assess whether the suggestive common variant enrichment results reported here reflect true biology related to psychiatric conditions.

The network can prioritize additional ASD risk genes from genetic studies
Since the combined PPI network is enriched for rare variants associated with ASDs, we used it to prioritize additional ASD risk genes that did not meet stringent statistical significance cutoffs in the exome sequencing study (10). Specifically, we generated a 'social Manhattan plot' to highlight protein interactions in the network between index genes and other ASD risk genes with FDR ≤ 0.25 in the exome sequencing data (Figure 7C). Consistent with the rare variant enrichment results, the overlap between our network and these ASD risk genes is statistically significant (P = 4.9e-4), with DYRK1A being linked to the most risk genes out of all the index genes. In total, we prioritized 32 ASD risk genes (13 with FDR ≤ 0.1 and 19 with FDR > 0.1 and ≤ 0.25) that are connected to at least one index gene in the network. Interestingly, these prioritized genes have elevated gene expression throughout cortical development that mirrors the high-. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint 29 confidence, exome-wide significant genes identified from exome sequencing (Supplementary Figure 6D). While follow-up investigation on these genes is necessary to better validate and evaluate our prioritization approach, this analysis showcases how the ASD PPI network is a unique resource that can be used to corroborate findings from recent GWAS and sequencing studies of ASDs, both in terms of building an exhaustive list of ASD risk genes and generating hypotheses of how these genes might contribute to ASDs mechanistically.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Discussion
ASDs are a heterogeneous set of heritable neurodevelopmental conditions with contributions from both rare and common genetic variants, and their genetic and biological complexity is reflected in the clinical diversity of ASD patients (9). In the past decade, rare variants with large effect sizes in protein-coding genes have been shown to significantly shift individual risk of ASDs during development and early childhood (11). In particular, a recent exome sequencing study identified 24 genes that contain an excess of rare deleterious mutations in ASD patients versus controls (10). However, how such ASD-associated mutations act singularly or in ensemble remains largely unknown (14,15). For instance, there is evidence that mutations in several of these genes result in similar mild impairments in social and communication skills (58).
In other cases, specific mutations are associated with altered brain size and other synaptopathies (59,60), but it is still unclear whether their function may converge on a single or restricted number of pathways and networks (14).
In this study, we combined human genetics, iPSC technology, computational modeling, and interaction proteomics to shed light on how a subset of ASD risk genes (index genes) may functionally converge in disease-relevant and brain cell type-specific pathways. Starting with the 24 high-confidence ASD index genes identified by exome sequencing (10), we performed extensive screening of immunoreagents amenable for IP of their encoded proteins, and . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  (63). We consolidated the iN-derived IP-MS data into a combined PPI network consisting of the 13 index proteins and 1,021 interactor proteins that represents, to our knowledge, the most extensive cell type-specific ASD PPI network thus far. We found that over 90% of the interactions in the network consists of interactions that have not been reported in the literature but are nevertheless highly reproducible (91.1% validation rate). This finding reflects the potential for biological discovery of neuronal-specific interactome proteomics, as opposed to relying on publicly available PPI datasets that are mostly populated by data collected in highly proliferative or immortalized cell types (e.g., HEK cells, cancer cell lines) (23, 34). We also performed IP-MS for a subset of index proteins in human brain samples and found that a significant portion of the iN-derived PPIs recapitulate interactions observed in the brain. Furthermore, the lower statistical power in the brain IP-MS data (i.e., lower replicate correlations and fewer significant interactions) supports our choice of executing interaction proteomics in more homogeneous, in vitro iNs instead of less abundant and non-renewable brain samples consisting of a complex mix of cell types. The neuronal relevance and specificity of the PPI network is further supported by its enrichment for genes expressed in brain tissues (36) and neuronal cell types (30).
We also observed a significant overlap between the network and differentially expressed genes in . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint the postmortem cortex of idiopathic ASD patients versus controls, specifically in layer 2/3 cortical excitatory neurons (30). This finding is of particular relevance given that such patients were not genetically characterized, suggesting that PPIs can be envisioned as a tool to stratify ASD patients in the future.
Our findings also illustrate how novel, brain-specific interactions within the PPI network can link ASD-associated genetic signals to relevant neuronal phenotypes. The ANK2 gene, for instance, encodes for two major protein isoforms as a result of alternative splicing. One protein isoform has a molecular weight of 220 kDa and is expressed in multiple tissues, while the other (commonly referred to as giant ANK2) has a molecular weight of 440 kDa due to the inclusion of exon 37 and is expressed only in the nervous system (39). Three human ANK2 ASD mutations (P1843S, R2608 frameshift, and E3429V) are located in exon 37 and thus only affect giant ANK2, whereas others (R895*, R990*, Q3683fs) affect both isoforms (64). In particular, a mouse model for human ASD mutation of giant ANK2 shows increased axonal branching and ectopic connectivity in cultured neurons, as well as a transient increase in excitatory synapses during postnatal development (38). In order to identify isoform-specific PPIs that may contribute to ANK2 function in axon guidance, we designed a giant ANK2 KO iPSC model and compared ANK2 IPs performed in the wild-type versus giant ANK2 KO NPCs and iNs. Our results suggest that giant ANK2 and its PPIs are essential for proper localization of cytoskeletal components to cell projections and maintenance of neuronal morphology. We were also able to recapitulate cellular phenotypes observed in mice, and concluded that they are the result of both primary lossof-function of neuronal proteins (likely due to mis-localization), and secondary effects linked to severely impaired cell morphogenesis.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint Another example of how the PPI network can be used to reconcile genetic signals with specific molecular mechanisms leading to cellular phenotypes resides in the newly characterized interaction between PTEN and AKAP8L. PTEN is frequently mutated in cancers due to its antagonizing role in PI3K/AKT/mTOR signaling (41), but germline mutations of PTEN have also been described in a subset of patients with autism combined with macrocephaly (42). However, there is no consensus on whether PTEN-mediated cell proliferation defects are tied to the neuronal phenotypes observed in ASDs. We found that knockout of the pseudo-kinase AKAP8L, the most robust interaction partner of PTEN in iNs, phenocopies its cellular phenotype. This discovery in iNs, together with the recently reported interaction between AKAP8L and mTORC1 (65), indicate that AKAP8L could be implicated in ASDs by bridging PTEN to key players in the mTOR pathway in human neurons. A previous study of a family with autism and macrocephaly has also identified AKAP8L as a likely candidate gene affected by the disease-associated genomic alteration at 19p13.12 (66), further supporting the hypothesis that the PTEN-AKAP8L interaction may influence neurodevelopmental phenotypes through the mTOR signaling cascades.
Our approach of generating a combined PPI network of multiple ASD index proteins also allowed us to experimentally identify functional convergence of these proteins based on their shared interactions (16,34,67). The hypothesis that ASD risk genes may act in a small number of networks has been long debated (15,68), and previous studies have only identified broad functional categories (e.g., "gene expression regulation", "neuronal communication", and "cytoskeleton") to be enriched among known ASD risk genes (10). In this study, we identified a number of proteins involved in RNA metabolism as being highly interconnected to multiple index proteins. Intriguingly, we found three components of the same complex (i.e., IGF2BP1, IGF2BP2, and IGF2BP3) to be among the most recurrent proteins in the network, each interacting with 5-7 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint index proteins. Insulin-like growth factor 2 mRNA-binding proteins 1-3 (IGF2BP1-3) belong to a conserved family of single-stranded RNA-binding proteins, and were recently characterized as part of a N6-methyladenosine (m6A)-reader complex broadly involved in post-transcriptional regulation by impacting mRNA stability and translation rates (44). Despite that their role in modulating individual neural stem cell growth and division has been explored in Drosophila (69), there is no previous evidence of their genetic associations to ASDs, which may be due to that fact at least two components of the complex, IGF2BP1 and IGF2BP3, are intolerant of LoF mutations in humans (52). Furthermore, when we analyzed published RNA targets of IGF2BP1-3 (44), we found that they are significantly enriched for ASD risk genes identified through exome sequencing, common variant risks of ASDs, as well as genes in our PPI network. In particular, we found the DYRK1A interactome to be strongly enriched for IGF2BP1-3 targets, and showed that partial knockdown of DYRK1A led to increased expression of IGF2BP1-3. These results suggest that the IGF2BP1-3 complex and DYRK1A might be part of a feedback mechanism reinforcing the expression of ASD-relevant transcripts. Importantly, these findings also showcase how convergent signals in the PPI network can be used to identify ASD-relevant genes and pathways that largescale genetic studies may fail to nominate due to either early embryonic lethality or sampling/statistical power limitations.
Finally, we show that the network is indeed statistically enriched for rare variant risks of ASDs and developmental disorders captured in exome sequencing data (10,50). Interestingly, the enrichment appears to be specific to these developmental phenotypes, as the same degree of enrichment was not observed for SCZ (51). Given these results, we integrated the network with ASD exome sequencing data in a 'social Manhattan plot' to demonstrate that it can be used to prioritize risk genes with suggestive significance in the genetic analysis, based on their interactions . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint with ASD index proteins in the network. Although we did not observe an enrichment for common variant risk of ASDs in the network, it is possible that this is due to statistical power limitations of the most recent ASD GWAS; we expect that with more data in the future, our network will also enable the prioritization of risk genes from GWAS data. This expectation is supported by our findings in a parallel study (co-submitted manuscript), where we applied the same brain cell typespecific interaction proteomics framework to generate an iN-derived PPI network for SCZ risk genes prioritized from GWAS loci. As well-powered, multi-ancestry GWAS datasets are available for SCZ, we found that the SCZ PPI network is enriched for common variant risk of SCZ in both Europeans and East Asians, and that the network can complement conventional strategies such as statistical fine-mapping and eQTL co-localization analyses to prioritize additional risk genes from GWAS loci. Repeating similar analyses for ASDs when larger GWAS datasets become available in the future may allow us to better determine if rare and common variant risks of ASDs generally converge onto shared pathways represented in the ASD PPI network, as we have already seen specifically for the transcriptional circuit regulated by IGF2BP1-3.
In conclusion, we built a PPI network of 13 index proteins encoded by high-confidence ASD risk genes in human iPSC-derived excitatory neurons. This network, which contains > 90% newly characterized interactions, is enriched for genes expressed in brain tissues and neuronal cell types, transcriptionally perturbed genes in the brains of idiopathic ASD patients, as well as genes containing rare deleterious mutations associated with ASDs and developmental disorders. We performed follow-up experiments and analyses to demonstrate that the network contains rich information for uncovering ASD-related biology, both in terms of investigating the individual PPIs (e.g., giant ANK2-specific PPIs and PTEN-AKAP8L interaction) and the convergent signals (e.g., IGF2BP1-3 complex) in the network. Overall, our findings not only bring clarity on how certain . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.07.21264575 doi: medRxiv preprint risk genes contribute to ASDs, but also suggest convergent biology and shared pathways that may inform therapeutic intervention or patient stratification strategies. Going forward, the approach described in this study and the parallel SCZ study (co-submitted manuscript) may be adapted and expanded to generate PPI networks for additional disease risk genes in various brain cell types in order to compile a comprehensive cell type-specific PPI atlas for psychiatric disorders.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.